Pharvaris
PHVS
60 hedge funds and large institutions have $793M invested in Pharvaris in 2025 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 19 increasing their positions, 16 reducing their positions, and 1 closing their positions.
800% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 1
19% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 16
15% more funds holding
Funds holding: 52 → 60 (+8)
7% more capital inflows, than outflows
Capital inflows: $24.5M | Capital outflows: $22.9M
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
0.55% less ownership
Funds ownership: 83.21% → 82.65% (-0.55%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Paradigm Biocapital Advisors
New York
|
+$17.1M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$2.92M |
| 3 |
TFG Asset Management
Grand Cayman,
Cayman Islands
|
+$984K |
| 4 |
ADAR1 Capital Management
Austin,
Texas
|
+$550K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$471K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VR Adviser
New York
|
-$17.2M |
| 2 |
Octagon Capital Advisors
New York
|
-$1.57M |
| 3 |
Soleus Capital Management
Greenwich,
Connecticut
|
-$1.32M |
| 4 |
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.19M |
| 5 |
Morgan Stanley
New York
|
-$251K |
PHVS Hedge Fund Activity: Q2 2025 in Review
60 of the 7,630 institutional investors tracked by Wall St. Rank reported a position in Pharvaris (PHVS) for Q2 2025, worth a combined $793M — up 12% from $706M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new PHVS positions and 1 closed out — a net gain of 8 holders — while 19 added to existing stakes and 16 trimmed.
The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $17.1M. The largest seller was VR Adviser, cutting an estimated $17.2M.
- 60 institutional investors held Pharvaris (PHVS) as of Q2 2025, up from 52 in Q1 2025.
- Funds reported $793M of Pharvaris stock for Q2 2025, up 12% quarter-over-quarter.
- 9 funds opened new Pharvaris positions in Q2 2025 and 1 closed out, a net change of +8 holders.
- The largest Pharvaris buyer in Q2 2025 was Paradigm Biocapital Advisors, an estimated $17.1M added.
- The largest Pharvaris seller in Q2 2025 was VR Adviser, an estimated $17.2M sold.
Based on aggregated 13F filings for Q2 2025.